Online inquiry

IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11658MR)

This product GTTS-WQ11658MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11658MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6964MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ5088MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ9267MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2257MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ15386MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ13964MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ10566MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ7687MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN3013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW